10.1 Infiltration & Extravasation
Key Takeaways
- Infiltration is non-vesicant fluid leaking into tissue; extravasation is vesicant leakage—the distinction drives urgency, antidote planning, and tissue-injury risk.
- Classic local signs include swelling, coolness, blanching, pain or burning, leakage at the site, and slowed or stopped infusion; absence of blood return alone is not reliable proof of a patent vessel.
- Immediate actions: STOP the infusion; do not automatically remove the catheter when residual vesicant aspiration or an antidote path is needed; aspirate residual drug, notify the provider, mark the area, and elevate—then apply thermal measures only as the agent dictates (many vesicants traditionally cold, vinca alkaloids traditionally warm), never by habit.
- Prevention centers on appropriate access for vesicants (central when required), securement, frequent site assessment, and never continuing an infusion when infiltration or extravasation is suspected.
- The INS Infiltration Scale grades 0-4 mainly by edema size—under 1 inch is Grade 1, 1-6 inches is Grade 2, and more than 6 inches is Grade 3—but infiltration of any amount of a blood product, irritant, or vesicant is automatically Grade 4 regardless of how small the swelling appears.
Definitions: infiltration vs extravasation
Quick Answer: Infiltration is leakage of a non-vesicant infusate into surrounding tissue. Extravasation is leakage of a vesicant (or other tissue-damaging agent) into tissue. Both can cause swelling and discomfort; extravasation can progress to blistering, necrosis, and long-term functional injury. On the exam, the first priority is always stop the infusion—never “turn it down and watch.”
Infusion nurses use precise language because treatment intensity differs. A cool, swollen peripheral site after isotonic crystalloid is serious and requires intervention, but a similar presentation during an anthracycline, vinca alkaloid, or other vesicant/irritant infusion is a tissue-emergency pathway. Some agents are classified as irritants (local inflammation without the classic necrosis profile of full vesicants) or exfoliants in oncology literature—facility and oncology protocols define lists. For CRNI purposes, master the non-vesicant vs vesicant distinction and the principle that agent identity drives next steps after you stop the infusion.
Vesicants (examples often tested in principle, not as exhaustive brand lists) include many anthracyclines (e.g., doxorubicin concepts), vinca alkaloids (e.g., vincristine, vinblastine concepts), and other agents identified in institutional extravasation policies. Non-vesicants include many routine crystalloids and non-irritating medications—still capable of compartment pressure and discomfort when large volumes extravasate.
Recognition: clinical signs and assessment traps
Assess the site before, during, and after infusions, especially with high-risk agents and continuous pumps. Cluster findings rather than relying on one sign:
| Finding | Why it matters |
|---|---|
| Swelling / edema near insertion or along the tract | Fluid collecting in interstitial tissue |
| Coolness of the skin | Infusate temperature/volume in tissue (often cooler than surrounding skin) |
| Blanching or taut, shiny skin | Interstitial pressure and circulatory compromise of superficial tissues |
| Pain, burning, stinging | Patient report is high-value—especially new or escalating pain at the site |
| Leakage at hub/dressing | Loss of closed system integrity or backtracking fluid |
| Slowing or stoppage of infusion / pump occlusion alarms | Resistance from tissue rather than open vein |
| Absence of free-flowing blood return | May support concern but is not diagnostic alone |
Why blood return is an unreliable sole test
A catheter can still yield blood return while fluid is leaking (partial malposition, multi-path flow) or fail to yield blood return while still infusing into a small vein. Never use “I got a flash” or “I could aspirate once” as permission to continue a painful, swollen infusion. Conversely, lack of blood return warrants investigation but is not, by itself, proof of extravasation. Exam stems that tempt you to continue based only on intermittent blood return are traps.
Compare both arms/sites when anatomy allows, palpate for firmness, ask about sensory changes, and correlate with pump history (how much volume has already run). Document baseline site condition at start of shift and at each assessment interval required by policy and therapy risk.
Immediate actions: the stop-first algorithm
When infiltration or extravasation is suspected:
- STOP the infusion immediately. Do not reduce rate “to see if it improves.”
- Do not remove the catheter immediately if residual drug aspiration or antidote administration through the existing catheter is part of the extravasation pathway. For many protocols, the line is a temporary tool to aspirate residual vesicant from the catheter and tissue interface before removal.
- Disconnect the administration set from the catheter hub while leaving the catheter in place as directed; attach a syringe and gently aspirate residual drug (do not flush residual vesicant deeper into tissue).
- Notify the provider / rapid response pathway per policy—especially for vesicants, large-volume infiltrates, or signs of compartment syndrome/neurovascular compromise.
- Mark the affected area (outline borders of swelling/erythema) and note time; photograph if policy permits for serial comparison.
- Elevate the limb when appropriate to reduce edema.
- Apply thermal therapy only per agent-specific protocol—see below.
- Administer antidotes only when ordered and indicated for that agent (examples of concepts: dexrazoxane pathways for certain anthracycline extravasations; hyaluronidase for selected agents/classes per protocol).
- Remove the catheter after residual aspiration/antidote steps as ordered; then provide site care, analgesia, and specialty follow-up (plastic surgery/oncology as indicated).
- Document thoroughly: drug, estimated volume, concentration, site, time discovered, actions, patient response, notifications, and education.
Exam trap: continuing the infusion
The classic wrong answer is to continue or restart the same peripheral site after “adjusting the arm” when clear infiltration signs are present. Another high-yield trap is removing the line before aspirating residual vesicant when protocol supports aspiration-first management.
Thermal applications: agent-specific, not habitual
Teach thermal measures as principles, not one-size-fits-all:
- Cold applications are traditionally used for many vesicants to cause local vasoconstriction and limit drug dispersion (exact lists live in oncology/extravasation protocols).
- Warm applications are classically associated with vinca alkaloids (and some other selected agents) to promote vasodilation and dispersal—again, protocol-driven.
- Non-vesicant infiltrates may use elevation and comfort measures; some protocols use warm compresses for certain non-vesicant irritants—follow the drug and facility algorithm.
On the exam, the safe cognitive pattern is: identify the agent class → apply the matching thermal rule from protocol → never invent heat/cold based on nurse preference. Wrong-temperature application can worsen tissue injury for some agents.
Antidotes and specialty pathways (concepts)
You are not expected to memorize every milligram of every antidote for every drug, but you must know that antidotes are agent-specific and order-driven:
- Dexrazoxane is the high-concept antidote pathway associated with anthracycline extravasation in many modern protocols (timing windows matter—early specialty involvement).
- Hyaluronidase is used for selected extravasations/infiltrates (including some non-cytotoxic agents and certain cytotoxic classes per protocol) to facilitate diffusion of the extravasated fluid.
- Specific antidotes for other agents exist in specialized lists (e.g., dimethyl sulfoxide concepts historically for some agents)—always defer to current institutional extravasation kit contents and oncology guidance.
Do not inject random antidotes “just in case.” Wrong antidote selection is harmful. Stop, aspirate, notify, and use the kit algorithm.
Prevention: design risk out of the system
Prevention is as testable as rescue:
- Match access to therapy: many vesicants require central vascular access when policy and drug properties demand it; peripheral administration of high-risk vesicants is a frequent root-cause theme in injury cases.
- Site selection: avoid areas of flexion when possible, avoid compromised limbs, and prefer sites that can be visualized and palpated frequently.
- Securement and dressing integrity: poorly secured catheters pistoning in the vein increase leak risk; loose dressings hide early swelling.
- Frequent assessment: high-risk infusions need closer observation intervals; educate patients to report burning or pain immediately—especially when pumps mask early resistance.
- Compatible devices and rates: verify patency before starting vesicants; avoid forcing infusions against resistance.
- Ultrasound and skilled placement for difficult access reduce multiple sticks and fragile sites.
- Never leave a questionable site “because the pump is still running.” Pumps can continue to force fluid into tissue until pressure alarms—clinical assessment overrides machine false reassurance.
Grading infiltration: the INS Infiltration Scale
The Infusion Therapy Standards of Practice publishes a 0–4 Infiltration Scale built on how far the edema extends plus skin and circulatory findings. The inch thresholds are the most commonly tested numbers in this topic.
| Grade | Clinical criteria (INS Infiltration Scale) |
|---|---|
| 0 | No symptoms |
| 1 | Skin blanched, edema <1 inch in any direction, cool to touch, with or without pain |
| 2 | Skin blanched, edema 1–6 inches in any direction, cool to touch, with or without pain |
| 3 | Skin blanched and translucent, gross edema >6 inches in any direction, cool to touch, mild–moderate pain, possible numbness |
| 4 | Skin blanched, translucent, tight and leaking, discolored, bruised, swollen; gross edema >6 inches; deep pitting tissue edema; circulatory impairment; moderate–severe pain; infiltration of any amount of blood product, irritant, or vesicant |
The highest-yield rule on this scale: infiltration of any amount of a blood product, irritant, or vesicant is Grade 4—no matter how small the swelling is. A 0.5 cm area of vesicant leak is not a "Grade 1"; it is a Grade 4 event that triggers the extravasation pathway. Exam stems exploit this by describing a tiny swelling with a chemotherapy agent and offering a low grade as an attractive distractor.
Reading the grades:
- Grades 1–3 are separated almost entirely by edema size: under 1 inch, 1–6 inches, over 6 inches.
- Translucency first appears at Grade 3; leaking, deep pitting edema, and circulatory impairment first appear at Grade 4.
- Coolness runs through Grades 1–3, because infiltrated fluid is typically cooler than tissue. Warmth points elsewhere—phlebitis or infection.
Document the grade and the objective findings behind it: measurements (compare limb circumferences), color, temperature, capillary refill distal to the site, sensory and motor status, and photographs when policy allows. Escalate for tense compartments, severe pain out of proportion, blistering, or evolving necrosis. Patient education covers what to watch for after discharge, because vesicant tissue injury can declare itself over hours to days.
Integrating with Domain 2 and therapy domains
Extravasation items often blend Access Devices with Infusion Therapies (antineoplastics). When a stem names a vesicant, shift from “simple infiltration care” to extravasation emergency pathway. When a stem names non-vesicant fluid with mild swelling, still stop and restart elsewhere—do not normalize ongoing peripheral leakage.
Master the sequence: recognize → stop → preserve catheter for residual aspiration when indicated → notify → mark/elevate/document → agent-specific thermal and antidote care → prevent the next event with better access planning. That sequence is the spine of CRNI performance for this topic.
Which definition correctly distinguishes extravasation from infiltration?
A patient receiving a peripheral vesicant reports burning; the site is cool, swollen, and blanched. What is the nurse’s first action?
Why is absence of blood return alone an unreliable way to rule out or confirm infiltration?
Which statement about thermal management after extravasation is most accurate for exam purposes?
A patient receiving peripheral doxorubicin develops a 0.5 cm area of swelling at the site with slight blanching. Using the INS Infiltration Scale, how is this graded and why?